Another message for you tonight and hope it is informative.
God Bless You,
marty auslander
CR for two of 19 with Onyx-015
-------------------------------
Onyx Pharmaceuticals of Richmond, Calif., said there were two
complete responses among 19 patients with refractory head-and-neck
cancer taking Onyx-015 (CI-1042) in a phase-2 trial. There were also
two partial responses and significant correlation between tumor-size
reduction and p53 gene status of the tumors, according to a report in
the November Cancer Research. Onyx’ stock shot up 12% on the news
before dropping back a bit. The tumor-selective, modified adenovirus
is also being investigated for pancreatic, ovarian, colorectal, and
lung cancer.
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
